Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium [177Lu]-BL-ARC001 in Advanced Solid Tumors
NCT07274852Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lutetium [177Lu] BL-ARC001 in lung cancer, breast cancer, head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose limiting toxicity at 42 days, Maximum tolerated dose at 42 days and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
Lutetium [177Lu] BL-ARC001
03
Conditions
lung cancerbreast cancerhead and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT07274852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274852.